Final report of a phase II study of imatinib mesylate with hyper-CVAD for the frontline treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia. Haematologica. 2015.
Detection of MRD may predict the outcome of patients with Philadelphia-chromosome positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013.